RJFSA
AXSM icon

Raymond James Financial Services Advisors’s Axsome Therapeutics AXSM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.38M Sell
15,379
-248
-2% -$21.6K ﹤0.01% 1951
2024
Q2 		$1.26M Sell
15,627
-1,694
-10% -$125K ﹤0.01% 1946
2024
Q1 		$1.38M Sell
17,321
-815
-4% -$68.4K ﹤0.01% 1863
2023
Q4 		$1.44M Sell
18,136
-598
-3% -$40K ﹤0.01% 1756
2023
Q3 		$1.31M Buy
18,734
+197
+1% +$14.7K ﹤0.01% 1763
2023
Q2 		$1.33M Buy
18,537
+1,744
+10% +$129K ﹤0.01% 1766
2023
Q1 		$1.04M Buy
16,793
+361
+2% +$23.7K ﹤0.01% 1877
2022
Q4 		$1.27M Buy
16,432
+490
+3% +$29.3K ﹤0.01% 1695
2022
Q3 		$711K Sell
15,942
-1,750
-10% -$87.4K ﹤0.01% 2043
2022
Q2 		$678K Hold
17,692
– – ﹤0.01% 2083
2022
Q1 		$732K Buy
+17,692
New +$548K ﹤0.01% 2148

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Raymond James Financial Services Advisors's AXSM Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Axsome Therapeutics (AXSM) stake by 1.6% in Q3 2024, selling an estimated $21.6K and leaving 15,379 shares worth $1.38M. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Raymond James Financial Services Advisors first reported a position in AXSM in Q1 2022 and has held it in 11 quarters since. The position peaked at $1.44M in Q4 2023. 279 funds tracked by Wall St. Rank hold AXSM as of Q3 2024.

  • Raymond James Financial Services Advisors held 15,379 shares of Axsome Therapeutics worth $1.38M as of Q3 2024.
  • Raymond James Financial Services Advisors sold 248 Axsome Therapeutics shares in Q3 2024, an estimated $21.6K.
  • Axsome Therapeutics made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #1951 holding.
  • Raymond James Financial Services Advisors first reported a position in Axsome Therapeutics in Q1 2022 and has held it in 11 quarters since.
  • Raymond James Financial Services Advisors's Axsome Therapeutics position peaked at $1.44M in Q4 2023.
  • 279 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.